Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

Market Cap	19.37B
Revenue (ttm)	2.51B
Net Income (ttm)	698.20M
Shares Out	1.67B
EPS (ttm)	0.42
PE Ratio	27.82
Forward PE	n/a
Dividend	0.30 (2.52%)
Ex-Dividend Date	May 23, 2025

Volume	81,674,754
Average Volume	110,961,162
Open	10.90
Previous Close	11.89
Day's Range	10.90 - 12.08
52-Week Range	7.38 - 13.06
Beta	0.44
RSI	62.45
Earnings Date	Aug 22, 2025

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 2,647
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300009

Financial Performance

In 2024, SHE:300009's revenue was 2.54 billion, a decrease of -11.51% compared to the previous year's 2.87 billion. Earnings were 706.95 million, a decrease of -16.56%.